Menu
Close
Global
×

Company News

Home Company News News detail
ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing
2023-03-23
514
Previous article：ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China
Next article：ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Back
Hot recommendation
2024-11-13
The Phase II clinical trial of IMM27M for estrogen receptor positive (ER+) advanced breast cancer that failed after endocrine therapy or recurred and has enrolled the first patient
More
2024-09-16
ImmuneOnco and Instil Bio Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, IMM2510/SYN-2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
More
2024-09-11
Further payment received under the license and collaboration agreement with SynBioTx for IMM2510 and IMM27M
More

For more information

Please follow the official wechat public account